Aerosolized prostacyclin for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS)
There is no current evidence to support or refute the routine use of aerosolized prostacyclin for patients with acute lung injury (ALI) and acute respiratory distress (ARDS).
ALI and ARDS are critical conditions that are associated with high mortality and morbidity. Aerosolised prostacyclin has been used to improve oxygenation despite the limited evidence available so far. This review assesses the benefits and harms of aerosolised prostacyclin in critically ill patients with acute lung injury and acute respiratory distress syndrome.
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.